A Phase 2 Study of BMS-986504 in People With Non-Small Cell Lung Cancer

Full Title

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies

Purpose

Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.

BMS-986504 blocks PRMT5, an enzyme that plays a role in cancer cell growth. BMS-986504 blocks processes that promote growth in MTAP-deleted cancer cells, while sparing cells without cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have NSCLC that has spread and is missing the MTAP gene.
• Have completed prior anti-cancer medications at least 4 weeks before taking BMS-986504 (2 weeks since radiation therapy).
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.